Skip to main content

Please wait ...

Michael Mithoefer, MD


Michael Mithoefer, MD, clinical assistant professor of psychiatry at the Medical University of South Carolina. In 2009, he completed & published the first FDA approved clinical trial of MDMA assisted psychotherapy for treatment-resistant PTSD, followed by completion of a Phase II trial. He is overseeing a multisite Phase III study of MDMA-assisted psychotherapy in 13 sites around the US (including the Trauma Research Foundation), and another MDMA-assisted psychotherapy multisite study in Europe and Israel.

 

Speaker Disclosures:
Financial: Dr. Michael Mithoefer has employment relationships with Columbia University, Bassett Healthcare Network, University of South Carolina, Lykos Therapeutics and has ownership interest in Awakn Life Sciences. He is a sub-investigator and therapist at Zen Therapeutics and a consultant with MAPS. Dr. Mithoefer receives a speaking honorarium and recording royalties from PESI, Inc.
Non-financial: Dr. Michael Mithoefer is a fellow of the American Psychiatric Association.

Products 1 through 4 out of 4

The Evolving Science of the Use of Psychedelic Substances in the Treatment of PTSD


Speakers:
Michael Mithoefer, MD
Copyright:
May 28, 2021
Media Type:
Digital Recording
Price:
£49.99 - Standard

Psychedelic-Assisted Psychotherapy for Complex Trauma: Core Principals and Clinical Applications for the Future of Trauma Treatment

Core Principals and Clinical Applications for the Future of Trauma Treatment

Speakers:
Linda Curran, BCPC, LPC, CAC-D, CCDPD, EMDR-C |  Michael Mithoefer, MD |  Victor Cabral, MSW, LSW, CCTP-I |  James W. Hopper, PhD |  Rosalind Watts, PhD |  Hannah McLane, MD, MA, MPH |  Stacia Butterfield |  Bessel A. van der Kolk, MD |  ....
Copyright:
Oct 03, 2023
Media Type:
Online Course
Price:
£189.98 Normal Price: Standard - £358.79

Pagination

Showing 1 to 4 of 4 entries